anti-Nipah_313
anti-Nipah_ID | anti-Nipah_313 |
anti-Nipah Drug | 3-[(5Z)-2,4-dioxo-5-[(5-phenylfuran-2-yl)methylidene]-1,3-thiazolidin-3-yl]propyl 4-{2-oxo-hexahydro-1H-thieno[3,4-d]imidazol-4-yl}butanoate |
Nipah virus strain | NiV (NiV-pVSV) |
Approaches used to test anti-Nipah activity | Experimental |
Methods used to test anti-Nipah activity | in-vitro |
Models used to test anti-Nipah activity | Vero |
Mode of infection to test anti-Nipah activity | Adsorption |
Viral titer to test anti-Nipah activity | NA NA |
Mode of Drug delivery for anti-Nipah activity | Culture |
Time of Drug delivery for anti-Nipah activity | Pre Infection |
Duration of Drug delivery for anti-Nipah activity | NA |
Drug concentration used to test anti-Nipah activity | >100 μM |
Assays used to test anti-Nipah activity | Plaque assay |
anti-Nipah activity | No significant difference [Inhibitory concentration (50 %)] |
References | Benhur Lee, Michael E. Jung, Michael C. Wolf, Tinghu Zhang Novel antiviral agents for enveloped viruses WO2010044924A |
Comments | The study documented a series of arylmethylidene rhodanine derivatives having broad- spectrum antiviral activity against enveloped viruses, including but not limited to f_loviruses, poxviruses, arenaviruses, bunyaviruses, paramyxoviruses, flaviviruses, influenza A, and HIV- 1. The compounds act via a novel mechanism to disrupt viral membranes and inhibit viral attachment, fusion, and/or entry into host cells. |